LIGHT (TNFSF14), is a key cytokine involved in T cell activation, lymphoid tissue development, and inflammatory pathogenesis. Its signaling through HVEM and LTβR promotes inflammation, tissue damage, and immune cell activation. By neutralizing soluble LIGHT, quisovalimab seeks to reduce the activation of pathogenic T cells and the production of inflammatory cytokines, potentially restoring immune homeostasis in chronic inflammatory diseases.